Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of PRI-724 against HCV or HBV liver cirrhosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kiminori Kimura, MD Komagome Hospital
Collaborators:
Japan Agency for Medical Research and Development Kyushu University National Center for Global Health and Medicine, Japan Ohara Pharmaceutical Co., Ltd. PRISM BioLab Co.,Ltd. Prism Pharma Co., Ltd.